Articles

admin

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights March 30, 2026 PDF Version Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across…

View details
Aura Biosciences to Participate in Upcoming Investor Conferences

February 25, 2026 PDF Version BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care…

View details
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors

October 10, 2024 SAN CARLOS, Calif., October 10, 2024 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious unserved orphan diseases, today announced the appointment of Joshua Grass as Chairperson of the Board. Mr. Grass succeeds Christopher Starr, Ph.D., who will continue to support the company as a scientific and clinical…

View details
2024 Sanford Burnham Prebys Rare Disease Day Symposium & CDG Family Conference

March 1, 2024 — March 3, 2024 https://www.glycomine.com/news/events In 2024, in partnership with CDG CARE and the Sanford Children’s Health Research Center, the Sanford Burnham Prebys Rare Disease Day Symposium will continue to focus on Congenital Disorders of Glycosylation “CDG Models and Therapy”. Researchers, clinicians, patients, family members, industry experts, and inspirational advocates will bring…

View details
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

2024-12-11 Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025. Barcelona, Spain and Düsseldorf, Germany – 11 December 2024 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central…

View details
Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study) 4 March 2025

 4 March 2025 Barcelona, Spain – 4 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study has been dosed with leriglitazone. TREE is a phase 2a clinical study assessing the safety and efficacy…

View details
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

November 12, 2024 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights. “This is a transformative time for our Company, as we presented the first…

View details